Drugs / White Button Mushroom Extract
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00779168 | Jan 2009 → Jun 2021 | prostate cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00709020 | Jun 2008 → Dec 2010 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04519879 | May 2021 → Oct 2026 | prostate adenocarcinoma | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04913064 | Jul 2021 → Jan 2027 expected | breast carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | White Button Mushroom Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04519879 ↗ |
| Known as | WBM | “To show that a whole food extract of white button mushrooms (WBM) can inhibit aromatase-induced estrogen biosynthesis in postmenopausal women who are breast cancer survivors (BCS).” NCT00709020 ↗ |
| Action | Inhibit | “can inhibit aromatase-induced estrogen biosynthesis” NCT00709020 ↗ |
| Modality | Other / unclassified | “provide a scientific foundation for WBM as a nutraceutical intervention to delay or prevent PCa progression” PMID 39390760 ↗ Oct 2024 |
| Route | Oral | “Patients receive oral white button mushroom extract twice daily for 12 weeks” NCT00709020 ↗ |